Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia - Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center) ; Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary) ; Robak, Tadeusz (Medical University of Lodz) ; Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda) ; Bairey, Osnat (Department of Hematology. Rabin Medical Center) ; Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente) ; Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital) ; Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University) ; McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department) ; Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology) ; Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company) ; Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ; Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ; Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center) ; Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele) ; Universitat Autònoma de Barcelona